Hepatitis C in pregnancy and the TiP-Hep C registry

CORRESPONDENCE| VOLUME 7, ISSUE 7, P598-599, JULY 01, 2022PDF [71
Neil Gupta,Lindsey Hiebert,Paige A Armstrong,Carolyn Wester,John W Ward
Published:July, 2022DOI:https://doi.org/10.1016/S2468-1253(22)00168-6

Over a fifth of hepatitis C virus (HCV) infections occur in women of childbearing age.
 At least 19 countries, including the USA, have policies or guidelines recommending universal HCV screening during pregnancy.
2However, options for management and treatment of HCV infection during pregnancy are not well defined. Typical clinical practice is to refer and link pregnant individuals for treatment after pregnancy and the breastfeeding period; however, in practice, very few are successfully treated.
3Despite an excellent safety profile, direct-acting antivirals (DAAs) are not recommended for use in pregnancy. To date, only one prospective clinical trial has been published assessing HCV treatment in pregnancy.4

To Continue:https://www.thelancet.com/journals/langas/article/PIIS2468-1253(22)00168-6/fulltext​